Estimated Glomerular Filtration Rate is not Associated with Alzheimer's Disease in a Northern Ireland Cohort by Paterson, Euan N et al.
Estimated Glomerular Filtration Rate is not Associated with
Alzheimer's Disease in a Northern Ireland Cohort
Paterson, E. N., Williams, M. A., Passmore, P., Silvestri, G., MacGillivray, T. J., Maxwell, A. P., & McKay, G. J.
(2017). Estimated Glomerular Filtration Rate is not Associated with Alzheimer's Disease in a Northern Ireland
Cohort. Journal of Alzheimer's disease : JAD. DOI: 10.3233/JAD-170480
Published in:
Journal of Alzheimer's disease : JAD
Document Version:
Peer reviewed version
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
© 2017 IOS Press.
This work is made available online in accordance with the publisher’s policies. Please refer to any applicable terms of use of the publisher.
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:04. Jan. 2018
1 
 
Title: Estimated glomerular filtration rate is not associated with Alzheimer’s disease in a 
Northern Ireland cohort. 
Running title: 
Renal function and Alzheimer’s disease 
 
Euan N. Paterson, B.Sc.a Michael A. Williams, M.D.,b Peter Passmore, M.D.,a Giuliana 
Silvestri, M.D.,c Tom J. MacGillivray, Ph,D.,d Alexander P. Maxwell, M.D.,a Gareth J. 
McKay, Ph.D.a 
aCentre for Public Health, Queen’s University Belfast,  
bCentre for Medical Education, Queen’s University of Belfast,  
cCentre for Experimental Medicine, Queen’s University of Belfast, and Belfast Health and 
Social Care Trust, Belfast, UK  
dCentre for Clinical Brain Sciences, The University of Edinburgh 
 
 
Corresponding author: 
Dr Gareth J McKay Ph.D. 
Centre for Public Health, Queen’s University Belfast 
+44 (0)28 9097 8958 
g.j.mckay@qub.ac.uk 
 
  
2 
 
Abstract 
Background: Alzheimer’s disease (AD) prevalence is increasing globally and typically 
progresses for several years prior to clinical presentation of dementia. Renal dysfunction and 
vascular disease have been reported in association with dementia in several cross-sectional and 
longitudinal studies, and may contribute to AD risk. Experimental and observational studies 
suggest amyloid-β (Aβ) clearance may be impaired in chronic kidney disease (CKD) indicating 
a mechanism for increased AD risk. Objective: The objective of this study was to compare 
estimated glomerular filtration rate (eGFR) between individuals with AD and cognitively intact 
controls, controlling for potential confounding factors. Methods: A cross-sectional, case-
control study was carried out in 317 cognitively normal participants and 253 cases with a 
clinical diagnosis of AD in a UK tertiary care dementia clinic. Associations were considered 
using logistic regression adjusting for confounding variables (age, APOE e4 genotype, systolic 
blood pressure, education (left school at 14), and smoking status). Results: AD cases were 
older than cognitively intact controls, had lower MMSE scores, were more likely to have at 
least one APOE e4 allele, had higher rates of smoking, were more likely to be taking aspirin 
and /or clopidogrel, and had lower blood pressure. We found no significant association between 
eGFR and AD both before and following adjustment for appropriate confounders. Conclusion: 
This study failed to find an association between eGFR and AD in a cross-sectional sample 
study of elderly white individuals. Keywords: Alzheimer disease, Chronic Renal 
Insufficiency, Dementia, glomerular filtration rate, kidney, Chronic Kidney Diseases. 
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Introduction 
Alzheimer's disease (AD) is the most common dementia subtype accounting for nearly 80% of 
all cases with the number of those affected likely to rise considerably with increasing life 
expectancy [1]. There are currently more than 815,000 people with dementia in the UK (about 
1.3% of the population) and 1 in 14 persons > 65 years have AD [2]. High prevalence rates 
have also been reported in the United States of America, with 1 in 9 individuals aged 65 years 
or more diagnosed with AD, increasing to 1 in 3 persons over the age of 85 years [3]. 
Chronic kidney disease (CKD) is characterised by a gradual loss of kidney function over 
months or years and identified by serial measurements of serum creatinine and estimated 
glomerular filtration rate (eGFR).  An eGFR < 60 ml/min/1.73m2 has been recognised as a 
potential risk factor for dementia [4–7].  The global prevalence of CKD is estimated at 11-13%, 
increasing with age to almost 28% in those 70 years or older [8]. Both the kidneys and brain 
are susceptible to vascular damage with similar haemodynamic and physiological 
characteristics and risk factors that include diabetes mellitus, hypertension and hyperlipidemia 
[9,10].  Renal dysfunction also accelerates vascular ageing and calcification, including the 
vasculature proximal to the brain, such as the circle of Willis [11], manifesting in structural 
alterations and increased risk of cerebrovascular disease [12].  
In preclinical dementia, symptomless but pathogenic changes within the brain include 
abnormal protein deposition culminating in neuronal death. Amyloid-β (Aβ) is the hallmark 
constituent of AD plaques and renal clearance has been proposed as a mechanism that aids the 
removal of cerebral Aβ [13]. An imbalance between the processes of production and clearance 
leads to Aβ accumulation and AD development and has become a therapeutic target of disease-
modifying agents [14]. CKD patients undergoing dialysis have been reported to have serum 
Aβ levels similar to cognitively intact controls, while those with CKD not receiving dialysis 
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had relatively higher serum Aβ levels that were negatively correlated with eGFR [15]. Systemic 
reduction in serum Aβ following haemodialysis has also been demonstrated [16] with 
associated improvement in cognitive function [17]. Furthermore, animal studies have shown 
renal clearance of peripheral Aβ has led to reduced cerebral levels in mice [18]. As such, the 
objective of this study was to compare renal function determined by eGFR, between individuals 
with AD and cognitively intact controls, controlling for potential confounding factors. 
 
Materials and Methods  
Study design and recruitment 
A cross-sectional, case-control study design was used to compare prevalent AD cases to 
cognitively intact controls. All recruitment and testing was undertaken between August 2006 
and 2008 by one investigator (MW) and has been described elsewhere [19]. An opportunistic 
recruitment strategy was used with probable AD cases identified in a non-systematic fashion 
as they appeared in a hospital memory clinic or from records of previous attendees diagnosed 
with probable AD by a senior clinician using the National Institute of Neurological and 
Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders 
Association (NINCDS ADRDA) criteria. Other dementia types such as vascular or mixed 
dementia were not included. Participants with AD were not excluded on the basis of a history 
of cerebrovascular disease. 
A variety of recruitment strategies were employed in the enrolment of controls from several 
sources. Firstly, carers of patients attending any outpatient clinic in the study hospital were 
approached. Secondly, a university press release invited participation in the study. Thirdly, a 
series of talks given to AD patient-support groups in the region led to further volunteers coming 
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forward. All participants provided informed consent prior to their entry into the study. 
Exclusion criteria for controls included age under 65 years or a Mini-Mental State Examination 
(MMSE) score below 26 out of 30. Ethics and governance approval was obtained prior to 
commencement of the study, which adhered to the tenets of the Declaration of Helsinki.  
Data collection 
Upon enrolment, all study participants underwent an assessment that involved measuring blood 
pressure, drawing a blood sample and performing a MMSE. The final component of the 
assessment involved the completion of questionnaires via interviews with the subject, as well 
as their carer when appropriate.  
Blood taken from participants using standard venepuncture was used to measure serum 
creatinine for eGFR using the CKD-EPI equation and for DNA extraction to determine APOE 
e4 genotype using a ‘Sequenom IPlex assay’ as well as other blood measures. A family history 
of AD, medication use and all co-morbid health conditions were documented as present or 
absent as determined by self-report or consultation of medical notes. Smoking history was 
measured as a cumulative dose in pack-years. 
Statistical Analysis 
Summary statistics for continuous variables and relative frequencies by group were calculated.  
Independent t-tests (for continuous variables) or chi-square tests (for categorical variables) 
were used to compare participant characteristics between cases and controls. Pearson’s 
correlation coefficients were performed to identify associations between cognitive indices with 
age and other continuous variables.  
Logistic regression models with dementia status (AD or control) as the outcome and eGFR as 
a continuous explanatory variable, were used to calculate odds ratios (OR) for AD with 95% 
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confidence intervals (CI), per unit increase in eGFR.  ORs were calculated before and after 
adjustment for confounders.  In the adjusted analysis, variables were eligible for inclusion in 
the final regression model if a significant association was found (p<0.05) following univariate 
analysis or if there was sufficient prior plausibility for their association with AD. To determine 
the final model, a backward selection procedure was undertaken and only variables 
significantly associated with the dependent variable (AD) were retained. Following this 
procedure the final model used to calculate adjusted OR’s contained age, number of APOE e4 
alleles, systolic blood pressure (SBP), smoking pack-years (calculated as the product of total 
years and average cigarettes per day) and educational attainment (recorded as leaving school 
before age fourteen or stayed in education beyond 14), and use of beta blockers. To examine 
the association between AD severity and eGFR, a sensitivity analysis was undertaken using 
multinomial logistic regression. AD severity was categorised by MMSE score: Severe: 0-9; 
Moderate: 10-20; Mild: 21-26; and pre-mild ≥ 27. Pre-mild AD was used as the reference 
category. The sensitivity analysis was adjusted for age, number of APOE e4 alleles, SBP, 
smoking pack-years, educational attainment and use of beta blockers.  All statistical analyses 
were performed using SPSS statistics version 23 (IBM Corp., Armonk, NY). 
 
Results 
Demographic and clinical characteristics of the study population (n=570) are presented in 
Table 1 for both cases (n=253) and controls (n=317).  AD patients were more likely to be older 
than controls (80.2 vs. 76.5 years; p<0.001), with at least one APOE e4 allele (69% vs. 25%; 
p<0.001). There was no significant difference in gender between cases and controls, with males 
constituting 36% of cases and 39% of controls. Cases with AD had a significantly lower MMSE 
score (18.0 vs. 28.8; p<0.001) and lower SBP (134 mmHg vs. 144 mmHg; p<0.001) compared 
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to control subjects. Of the AD cases, 26 (10%) were categorised with severe AD (MMSE 0-9), 
103 (41%) with moderate AD (MMSE 10-20), 81 (32%) with mild AD (MMSE 21-26), and 7 
(3%) with pre-mild (MMSE ≥ 27). Markedly higher proportions of patients with AD had left 
school at or before 14 years of age (58% vs. 45%; p<0.01) compared to cognitively intact 
controls. Furthermore, on average patients with AD had accumulated twice as many smoking 
pack-years as participants in the control group (17.7 vs. 10.0 pack-years; p<0.01). No 
significant differences were detected between AD cases and controls for history of diabetes 
mellitus, cardiovascular disease, cerebrovascular disease, or hypercholesterolemia (Table1).A 
significantly greater proportion of AD patients were taking aspirin and/ or clopidogrel (48% 
vs. 39%; p=0.02) and non-thiazide diuretics (14% vs. 8%; p=0.03), than controls (Table 1). No 
difference in renal function was found between cases and controls (37.3 ml/min/1.73m2 vs 37.4 
ml/min/1.73m2; p= 0.94).  In a multivariate logistic regression (Table 2) there was no 
significant difference in eGFR between those with AD and cognitively intact controls 
following adjustment for APOE genotype, age, SBP, smoking status, educational status and 
beta blocker use (OR = 1.01; CI: 0.98-1.04; p = 0.50).  In the sensitivity analysis of AD severity 
in cases only (categorised by MMSE score), no associations were reported between eGFR and 
AD severity categories following adjustment for APOE genotype, age, SBP, smoking status, 
educational status and beta blockers (data not shown). 
 
Discussion 
We found no significant association between eGFR and AD in this case-control study of 570 
participants in an analysis adjusted for established AD risk factors.  Additionally, we found no 
association between eGFR and disease severity as defined by MMSE score in AD cases only.  
Our findings support previous reports that showed no association between eGFR and cognitive 
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impairment [6,20–22], but contrast to those that did report a significant association [5,9,23–
30]. In addition, other studies also reported significant associations between renal impairment 
characterised by the presence of microalbuminuria and cognitive impairment [10,20,21,31]. A 
recent meta-analysis of five population based prospective studies included 27,805 participants, 
demonstrated a non-significant increased risk of cognitive impairment or dementia in those 
with an eGFR < 60 ml/min/1.73m2, with a significant association found only in those with 
albuminuria [7].  
Unlike previous studies that examined cognitive impairment or dementia, we focused 
specifically on eGFR in AD. In an earlier study by this group with a smaller sample size and 
better renal function (eGFR > 60 ml/min/1.73m2), an association between lower eGFR in 83 
AD cases was identified compared to cognitively intact controls which remained significant 
following adjustment for known risk factors [4]. Other case-control studies of similar size have 
also reported lower eGFR in AD cases compared to  controls [32,33] providing some support 
for the hypothesis that reduced renal function contributes to impaired Aβ clearance and 
increased cerebral deposition [13–18,34]. Our current findings support data from the 
Cardiovascular Health Cognition Study in 3,349 individuals, where an association with serum 
creatinine and vascular dementia was identified but not in those with AD [35]. Our findings 
were based on a largely clinically derived sample of older participants (mean age 78) with 
unexpectedly poor renal function compared to the same age group in other cohorts [36] for 
both cases and controls (eGFR = 37 ml/min/1.73m2). Rates of hypertension and diabetes were 
not higher than expected in cases or controls. The low renal function observed in this study 
may result in part from the sampling method used. Any sampling bias favouring inclusion of 
participants with poor renal function would have increased the risk of type 2 error in this study. 
Recruitment of carers may have resulted in higher proportions of first-degree relatives and 
spousal recruitment. Spousal concordance of health risks and behaviours has been reported for 
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many diseases, including CKD and other conditions influenced by renal risk factors, such as 
cardiovascular disease, hypertension, metabolic syndrome, and elevated fasting glucose levels 
[37,38]. 
We used a serum creatinine based equation to estimate renal function and eGFR [39]. Other 
studies have shown that cystatin-C may be a more accurate indicator of GFR than serum 
creatinine in populations with more extensive co-morbidities [40]. Cystatin-C accumulates in 
the blood of those with CKD and may reduce AD risk by binding Aβ and inhibiting its 
deposition in the brain [41]. 
Major strengths of the present study were its reasonable sample size and extensive 
characterisation of the study population that enabled adjustment for major potential 
confounders. However, there are several potential limitations to our study. First, there may be 
residual confounding factors not measured in our sample that influence renal function but 
which have not been controlled for in our data. Second, any causal and temporal relationships 
between eGFR and AD cannot be determined due to the cross-sectional nature of our study, 
which prevents the inference of any causal or chronological relationship.  Thirdly, the absence 
of direct measures of glomerular filtration rate limits the assumptions inferred from the eGFR 
formula which was based on a single laboratory measurement.  Fourth, the potential for 
confounding bias may have been introduced through differences in the strategies for recruiting 
cases and controls.  Fifth, the definition used for cognitively normal controls, MMSE ≥ 26, 
may have resulted in the inclusion of small number of individuals with prodromal AD.  Finally, 
other methodological issues may further complicate the interpretation of our data. While the 
convenience sampling was instrumental in the recruitment of 570 participants in a timely 
manner, this approach may have inhibited subject demographics and limited the 
generalisability of conclusions.  Future studies should aim to adopt a truly random approach to 
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recruitment, using population records for identifying controls and a comprehensive AD patient 
database to sample cases.  
This study provides cross-sectional evidence in a large sample that eGFR is not associated with 
AD in an elderly white population with poor renal function.  
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Table 1: Summary statistics of subject characteristics. 
Characteristic 
All  
(n=570) 
Controls 
(n=317) 
Cases 
(n=253) 
P-value 
Mean age, yrs (SD) 78.1 (7.4) 76.5 (6.7) 80.2 (7.7) <0.001 
Male, n (%) 216 (38) 125 (39) 91 (36) 0.40 
Mean MMSE (SD) 24.4 (6.8) 28.8 (1.2) 18.0 (6.5) <0.001 
Presence of APOE e4 allele, n (%) 240 (45) 71 (25) 169 (69) <0.001 
Mean systolic blood pressure, mmHg (SD) 139 (18) 144 (18) 134 (18) <0.001 
Mean eGFR CKD-EPI,  ml/min/1.73m2 (SD) 37.4 (8.9) 37.3 (8.4) 37.4 (9.4) 0.94 
Education –left school at 14, n (%) 274 (48) 138 (45) 136 (58) <0.01 
Never smoked, n (%) 321 (59) 191 (62) 130 (54) 0.10 
Diabetes mellitus, n (%) 59 (10) 37 (12) 22 (9) 0.28 
Hypertension, n (%) 221 (39) 131 (43) 90 (38) 0.25 
Cardiovascular disease, n (%) 129 (23) 76 (25) 53 (22) 0.47 
Cerebrovascular disease, n (%) 70 (12) 38 (12) 32 (13) 0.74 
Hypercholesterolaemia, n (%) 216 (38) 124 (41) 92 (39) 0.68 
Aspirin and /or clopidogrel, n (%)* 229 (40) 116 (39) 113 (48) 0.03 
Antacids, n (%)* 144 (27) 71 (24) 73 (31) 0.06 
Thiazide, n (%)* 100 (19) 54 (19) 46 (20) 0.70 
Non-thiazide diuretics, n (%)* 57 (11) 24 (8) 33 (14) 0.03 
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Abbreviations: SD, standard deviation; MMSE, Mini-Mental State Examination; eGFR CKD-
EPI, Estimated glomerular filtration rate calculated using the CKD-EPI equation; NSAIDs, 
non-steroidal anti-inflammatory drugs; CCBs, calcium channel blockers. 
*Medications recorded with a frequency >5%. 
NSAIDs, n (%)* 33 (6) 22 (7) 11 (5) 0.20 
Thyroxine, n (%)* 59 (11) 30 (10) 29 (12) 0.39 
CCBs, n (%)* 62 (12) 28 (10) 34 (15) 0.08 
Beta blockers, n (%)* 118 (23) 75 (26) 43 (19) 0.05 
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Table 2: Estimated glomerular filtration rate association in subjects with Alzheimer’s 
disease and controls  
Variable  Odds ratio (95% CI) p-value 
   
APOE e4 alleles 5.85 (3.82 – 8.95) <0.001 
Age (years) 1.08 (1.04 - 1.12) <0.001 
Systolic blood pressure 0.97 (0.96 - 0.99) <0.001 
Smoking (packyears) 1.01 (1.00 - 1.02) 0.02 
Education > 14 years 1.67 (1.05 - 2.67) 0.03 
Beta blockers 2.07 (1.16 – 3.68 0.01 
eGFR (CKD-EPI) 1.01 (0.98 - 1.04) 0.50 
Abbreviations: SD, standard deviation; OR, odds ratio; CI, confidence intervals; eGFR (CKD-
EPI), Estimated glomerular filtration rate calculated using the CKD-EPI equation. 
*Multiple logistic regression analysis adjusted for age (years), number of APOE e4 alleles, 
smoking (pack years), systolic blood pressure (mmHg), education (leaving school at or before 
14), beta blockers. 
 
